每周一次胰岛素icodec与每日一次甘精胰岛素U100在未使用胰岛素的2型糖尿病患者中的持续葡萄糖监测指标及低血糖事件持续时间:ONWARDS 1探索性分析
ONWARDS 1试验的探索性分析纳入未使用过胰岛素的2型糖尿病患者,比较每周一次icodec与每日一次甘精胰岛素U100的CGM指标。结果显示治疗中后期icodec的TIR和TITR显著更高、TAR显著更低,TIR达到国际推荐目标,两组低血糖持续时间相似(中位≤35分钟)。
要点
- 治疗中后期,icodec组TIR和TITR平均百分比显著高于甘精U100组,TAR显著更低。
- icodec组TIR达到国际推荐目标(>70%),甘精U100组未达到。
- 两组TBR均低于推荐目标,低血糖事件持续时间相似(中位≤35分钟)。
核心结论
- CGM数据支持icodec相较于甘精胰岛素U100在治疗期间的长期疗效和安全性。
- 在未使用过胰岛素的2型糖尿病患者中,icodec相较于甘精胰岛素U100未增加单次低血糖事件的持续时间。
研究设计与样本
- ONWARDS 1是一项为期78周(52周主要治疗期和26周延伸治疗期加5周随访)的随机、开放标签、达标治疗、3a期试验。
- 在12个国家的143个中心(门诊和医院科室)进行,成人(≥18岁)2型糖尿病(HbA1c 7.0-11.0%)且既往未接受胰岛素治疗者按1:1随机分配至每周一次icodec或每日一次甘精胰岛素U100。
- 双盲CGM数据在治疗起始(第0-4周)、试验中期(第22-26周)、主要阶段结束(第48-52周)、延伸阶段结束(第74-78周)和随访(第78-83周)收集。
- 分析基于全分析集(所有随机分配参与者),每组492例。
主要发现
- 治疗起始期,icodec与甘精胰岛素U100在TIR、TITR、TAR和TBR平均百分比上无统计学显著差异。
- 试验中期、主要阶段结束和延伸阶段结束期,icodec组TIR和TITR平均百分比显著高于甘精胰岛素U100组,TAR平均百分比显著低于甘精胰岛素U100组。
- 上述三个时期,icodec组TIR平均百分比达到国际推荐CGM目标(>70%),甘精胰岛素U100组未达到。
- 所有研究期间两组TBR(<3.9 mmol/L和<3.0 mmol/L)均较低且低于推荐目标(分别<4%和<1%),较低阈值(<3.0 mmol/L)两组间无统计学显著差异。
- 随访期间,icodec与甘精胰岛素U100的TIR、TITR、TAR和TBR平均百分比无统计学显著差异;整个试验中两组总体低血糖事件持续时间相似(中位持续时间≤35分钟)。
关键数值与推荐
- TIR定义为传感器葡萄糖3.9-10.0 mmol/L(70-180 mg/dL)的时间百分比。
- TITR定义为3.9-7.8 mmol/L(70-140 mg/dL)的时间百分比。
- TAR定义为>10.0 mmol/L(>180 mg/dL)的时间百分比;TBR定义为<3.9 mmol/L(<70 mg/dL)和<3.0 mmol/L(<54 mg/dL)的时间百分比。
- CGM衍生的低血糖事件定义为传感器葡萄糖<3.9 mmol/L(<70 mg/dL)持续≥15分钟。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Continuous glucose monitoring (CGM) can provide a comprehensive assessment of glycaemic control. This exploratory analysis of the ONWARDS 1 trial assessed CGM-based metrics and CGM-derived hypoglycaemia duration in insulin-naive individuals with type 2 diabetes treated with subcutaneous once-weekly insulin icodec (icodec) versus once-daily insulin glargine U100 (glargine U100). METHODS: ONWARDS 1 was a 78-week (52-week main treatment phase and a 26-week treatment extension phase plus a 5-week follow-up), randomised, open-label, treat-to-target, phase 3a trial done at 143 sites (outpatient clinics and hospital departments) across 12 countries. Adults (aged ≥18 years) with type 2 diabetes (HbA1c: 7·0-11·0%) who had not previously received insulin were randomly assigned (1:1) via an interactive web-response system to once-weekly icodec or once-daily glargine U100. Double-masked CGM data were collected during treatment initiation (weeks 0-4), midtrial (weeks 22-26), end of main phase (weeks 48-52), end of extension phase (weeks 74-78), and follow-up (weeks 78-83). Secondary and exploratory outcomes were CGM-based metrics, including the mean percentages of time in glycaemic range (TIR; sensor glucose 3·9-10·0 mmol/L [70-180 mg/dL]), time in tight range (TITR; 3·9-7·8 mmol/L [70-140 mg/dL]), time above range (TAR; >10·0 mmol/L [>180 mg/dL]), and time below range (TBR; <3·9 mmol/L [<70 mg/dL] and <3·0 mmol/L [<54 mg/dL]), and CGM-derived hypoglycaemic episode durations (episodes defined by sensor glucose <3·9 mmol/L [<70 mg/dL for ≥15 consecutive minutes]). Analyses were done in the full analysis set (all randomly assigned participants). The ONWARDS 1 trial is registered with ClinicalTrials.gov, NCT04460885, and is complete. FINDINGS: Participants were enrolled and randomly assigned in ONWARDS 1 between Nov 25, 2020, and Dec 1, 2022 (n=492 in each treatment group). During treatment initiation, we observed no statistically significant differences in the mean percentages of TIR, TITR, TAR, and TBR with icodec versus glargine U100. During the midtrial, end of main phase, and end of extension phase periods, the mean percentages of TIR and TITR were statistically significantly greater and the mean percentages of TAR statistically significantly lower with icodec versus glargine U100. The mean percentages of TIR met the internationally recommended CGM target (>70%) with icodec but not with glargine U100 during the three periods. TBR (<3·9 mmol/L [<70 mg/dL] and <3·0 mmol/L [<54 mg/dL]) was low and below recommended targets (<4% and <1%, respectively) across all study periods in both treatment groups, with no statistically significant differences between treatment groups for the lower threshold (<3·0 mmol/L [<54 mg/dL]). During the follow-up period, mean percentages of TIR, TITR, TAR, and TBR did not statistically significantly differ with icodec versus glargine U100. The duration of overall hypoglycaemic episodes was similar between treatment groups throughout the trial (median duration ≤35 min). INTERPRETATION: These CGM data support the long-term efficacy and safety of icodec versus glargine U100 during treatment and indicated no increase in the duration of individual hypoglycaemic episodes with icodec versus glargine U100 in insulin-naive individuals with type 2 diabetes. FUNDING: Novo Nordisk.
引用
- Bergenstal RM, Ásbjörnsdóttir B, Watt SK, et al. Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1. Lancet Diabetes Endocrinol. 2024. PMID: 39374601. doi:10.1016/S2213-8587(24)00220-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。